These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20007759)

  • 41. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.
    Schroeder JA; Weingart C; Coras B; Hausser I; Reinhold S; Mack M; Seybold V; Vogt T; Banas B; Hofstaedter F; Krämer BK
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):968-75. PubMed ID: 18385397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 43. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
    Grobner T
    Nephrol Dial Transplant; 2006 Apr; 21(4):1104-8. PubMed ID: 16431890
    [No Abstract]   [Full Text] [Related]  

  • 46. Gadolinium deposits could influence the course of encapsulating peritoneal sclerosis.
    Latus J; Goffin E; Schroeder JA; Fritz P; Ott G; Ulmer C; Steurer W; Kimmel M; Biegger D; Segerer S; Alscher MD; Braun N
    Perit Dial Int; 2014; 34(5):561-5. PubMed ID: 25075001
    [No Abstract]   [Full Text] [Related]  

  • 47. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.
    Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C
    Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis.
    Steger-Hartmann T; Hofmeister R; Ernst R; Pietsch H; Sieber MA; Walter J
    Invest Radiol; 2010 Sep; 45(9):520-8. PubMed ID: 20644486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
    J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis.
    Morelle J; Sow A; Hautem N; Bouzin C; Crott R; Devuyst O; Goffin E
    J Am Soc Nephrol; 2015 Oct; 26(10):2521-33. PubMed ID: 25636412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
    Jikki PN
    J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
    [No Abstract]   [Full Text] [Related]  

  • 52. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
    Khurana A; Greene JF; High WA
    J Am Acad Dermatol; 2008 Aug; 59(2):218-24. PubMed ID: 18538448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of a screening instrument for nephrogenic systemic fibrosis.
    Lima XT; Alora-Palli MB; Kimball AB; Kay J
    Arthritis Care Res (Hoboken); 2013 Apr; 65(4):637-42. PubMed ID: 23097320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gadolinium-based contrast agents and NSF: evidence from animal experience.
    Sieber MA; Steger-Hartmann T; Lengsfeld P; Pietsch H
    J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients.
    Tawada M; Ito Y; Hamada C; Honda K; Mizuno M; Suzuki Y; Sakata F; Terabayashi T; Matsukawa Y; Maruyama S; Imai E; Matsuo S; Takei Y
    PLoS One; 2016; 11(4):e0154644. PubMed ID: 27119341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update on nephrogenic systemic fibrosis.
    Thomsen HS; Marckmann P; Logager VB
    Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.
    Grant D; Johnsen H; Juelsrud A; Løvhaug D
    Acta Radiol; 2009 Mar; 50(2):156-69. PubMed ID: 19160079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.